Priya Singhal
Overview
Explore the profile of Priya Singhal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen T, OGorman J, Castrillo-Viguera C, Rajagovindan R, Curiale G, Tian Y, et al.
Alzheimers Dement
. 2024 Apr;
20(5):3406-3415.
PMID: 38567735
Introduction: Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer's disease (AD). Methods: PRIME was a Phase 1b, double-blind, randomized clinical trial of aducanumab. During...
2.
Guruprasad Y, Singhal P, Gupta N, Kukreja B, Gupta B, Kukreja P, et al.
Bioinformation
. 2024 Feb;
19(13):1399-1404.
PMID: 38415034
Evaluation of immuno-histochemical (IHC) markers like p53, p63, PDPN, C-erb-B2, CK19, and VEGF in oral squamous cell carcinoma (OSCCs) is of interest to dentists. Sixty formalin-fixed paraffin embedded tissue blocks...
3.
Debnath A, Sharma S, Mazumder R, Mazumder A, Singh R, Kumar A, et al.
Curr Drug Discov Technol
. 2023 Dec;
21(3):20-31.
PMID: 38047361
Background: Type 2 diabetes mellitus constitutes approximately 90% of all reported forms of diabetes mellitus. Insulin resistance characterizes this manifestation of diabetes. The prevalence of this condition is commonly observed...
4.
Dsilva L, McCarthy K, Lyons J, Cabigas B, Campbell N, Kong G, et al.
Expert Opin Drug Saf
. 2023 Jun;
22(10):995-1002.
PMID: 37272350
Background: Progressive multifocal leukoencephalopathy (PML), an important identified risk for natalizumab, has been described for standard interval dosing (SID; dosing interval every-4-weeks). Information on PML with natalizumab extended interval dosing...
5.
Lyons J, Hughes R, McCarthy K, Everage N, Kapadia S, Miller C, et al.
Mult Scler J Exp Transl Clin
. 2022 Nov;
8(4):20552173221132469.
PMID: 36387034
Background And Objectives: Dimethyl fumarate (DMF), an oral disease-modifying therapy with an established benefit and well-described safety profile, is among the most commonly used therapies for relapsing forms of multiple...
6.
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al.
JAMA Neurol
. 2021 Nov;
79(1):13-21.
PMID: 34807243
Importance: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an...
7.
Judson M, Elicker B, Colby T, Kwon S, de Windt E, Chalkias S, et al.
Respir Med
. 2019 Mar;
149:23-27.
PMID: 30885425
Introduction: Several drugs have been associated with druginduced sarcoidosis-like reactions (DISRs) that are clinically indistinguishable from sarcoidosis. Daclizumab is a humanized monoclonal IgG1 antibody that binds to CD25 that has...
8.
Hulse R, Beazley-Long N, Ved N, Bestall S, Riaz H, Singhal P, et al.
Clin Sci (Lond)
. 2015 Jul;
129(8):741-56.
PMID: 26201024
Diabetic peripheral neuropathy affects up to half of diabetic patients. This neuronal damage leads to sensory disturbances, including allodynia and hyperalgesia. Many growth factors have been suggested as useful treatments...
9.
Roujeau J, Mockenhaupt M, Tahan S, Henshaw J, Martin E, Harding M, et al.
JAMA Dermatol
. 2013 Apr;
149(2):152-8.
PMID: 23560295
Objective: To evaluate the incidence, type, and severity of telaprevir-associated skin reactions. Design: Three dermatologists assessed available information including photographs, biopsy results, and clinical summaries of all cases with skin...